drugset / Trial / NCT00143572
Use of Hydroxyurea and Magnesium Pidolate for Treatment of Sickle Cell Disease
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to estimate the MTD of Mg pidolate in combination with HU in patients with sickle cell disease who have been on a therapeutic dose (15-30 mg/kg/day) of HU for at least 6 months.
Timeline
- Start
- 2004-11
- Primary completion
- 2008-01
- Completion
- 2008-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Magnesium Pidolate | Unknown | 0.6 meq | — |
| Background | Hydroxyurea | Other / unclassified | — | — |